Inventor
Stanley L. Hazen
Inventor
Pepper Pike, OH, US
Overview
Patents· 48 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
G01Nprimary
G01NInvestigating or analysing materials by determining their chemical or physical properties18%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%
A61KPreparations for medical, dental or toiletry purposes15%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms9%
Y02ATechnologies for adaptation to climate change6%
C07KPeptides5%
C12NMicroorganisms or enzymes4%
C12YEnzymes4%
G16HHealthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data4%
G16ZInformation and communication technology [ict] specially adapted for specific application fields, not otherwise provided for4%
PatentTitleYear
10,983,100Trimethylamine-containing compounds for diagnosis and prediction of disease202110,933,072Treating and preventing disease with TMA and TMAO lowering agents202110,849,866Methods for inhibiting conversion of choline to trimethylamine (TMA)202010,786,479Methods for inhibiting conversion of carnitine to trimethylamine (TMA)202010,780,072Methods for inhibiting conversion of choline to trimethylamine (TMA)202010,751,301Methods for inhibiting conversion of choline to trimethylamine (TMA)202010,675,256Methods for inhibiting conversion of choline to trimethylamine (TMA)202010,613,044NMR quantification of TMAO202010,551,372Trimethylamine compounds as risk predictors of cardiovascular disease202010,241,093Trimethylamine-containing compounds for diagnosis and prediction of disease201910,213,407Compounds and methods for inhibiting production of trimethylamine201910,117,879Treating and preventing disease with TMA and TMAO lowering agents201810,064,830Treatment and prevention of cardiovascular disease and thrombosis20189,694,020'Treating and preventing disease with TMA and TMAO lowering agents'20179,612,242'Combined F2-isoprostane and myleoperoxidase detection, a risk indicator for cardiovascular disease'20179,581,597'Myeloperoxidase, a risk indicator for cardiovascular disease'20179,575,065'Myeloperoxidase, a risk indicator for cardiovascular disease'20179,541,620'NMR quantification of TMAO'20179,522,950'Oxidant resistant apolipoprotein A-1 and mimetic peptides'20169,435,808'Myeloperoxidase, a risk indicator for cardiovascular disease'20169,423,405'Trimethylamine compounds as risk predictors of cardiovascular disease'20169,410,938'Biomarkers for asthma'20169,365,888'Assessing the risk of a major adverse cardiac event in patients with chest pain'20169,365,889'PON1 as a marker for heart failure'20169,265,736'Treatment of cardiovascular disease and thrombosis'20169,168,233'Treatment and prevention of cardiovascular disease and thrombosis'20159,170,260'Myeloperoxidase, a risk indicator for cardiovascular disease'20159,164,095'Myeloperoxidase, a risk indicator for cardiovascular disease'20159,140,703'Combined F2-isoprostane and myeloperoxidase detection, a risk indicator for cardiovascular disease'20159,086,425'Carbamylated proteins and risk of cardiovascular disease'20159,051,393'Oxidant resistant apolipoprotein A-1 and mimetic peptides'20159,005,904'Risk markers for cardiovascular disease'20158,722,344'Risk markers for cardiovascular disease'20148,628,935'PON1 as a marker for heart failure'20148,536,117'Oxidant resistant apolipoprotein A-1 and mimetic peptides'20138,349,581'Assessing the risk of a major adverse cardiac event in patients with chest pain'20138,338,110'Risk markers for cardiovascular disease'20128,309,320'Diagnosis of conditions associated with decreased arginine bioavailability'20128,143,224'Oxidant resistant apolipoprotein A-1 and mimetic peptides'20127,781,219'Risk markers for cardiovascular disease'20107,780,950'Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents'20107,776,563'Methods for identifying agents for treating cardiovascular disease using inhibition of myeloperoxidase binding'20107,771,954'Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents'20107,648,840'Diagnosis of conditions associated with decreased arginine bioavailability'20107,491,504'Method for detecting ovarian cancer'20097,459,286'Assessing the risk of a major adverse cardiac event in patients with chest pain'20087,378,396'Therapeutic agents and methods for cardiovascular disease'20087,223,552'Myeloperoxidase, a risk indicator for cardiovascular disease'2007Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2007–2016Patents assigned to CLEVELAND CLINIC FOUNDATION (26)· patent assignee history
2007–2021Based in Pepper Pike, OH, US· patent location history
2009Based in Gates Mills, OH, US· patent location history
2010–2012Based in Cleveland, OH, US· patent location history
2012–2019Patents assigned to HAZEN STANLEY L (13)· patent assignee history
2013–2016Patents assigned to ZHANG RENLIANG (5)· patent assignee history
2016–2021Patents assigned to CLEVELAND CLINIC FOUND (20)· patent assignee history
2019–2020Patents assigned to PROCTER & GAMBLE (6)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CLEVELAND CLINIC FOUNDATION | 26 | 2007–2016 |
| CLEVELAND CLINIC FOUND | 20 | 2016–2021 |
| HAZEN STANLEY Lself | 13 | 2012–2019 |
| PROCTER & GAMBLE | 6 | 2019–2020 |
| ZHANG RENLIANG | 5 | 2013–2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| Pepper Pike, OH, US | 45 | 2007–2021 |
| Cleveland, OH, US | 2 | 2010–2012 |
| Gates Mills, OH, US | 1 | 2009 |